Adagene Inc. Files 6-K with Mid-Year Financial Updates
Ticker: ADAG · Form: 6-K · Filed: 2024-07-25T00:00:00.000Z
Sentiment: neutral
Topics: financial-update, 6-k, sec-filing
TL;DR
Adagene's 6-K shows Q2 financial snapshot; check capital structure changes.
AI Summary
Adagene Inc. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the first six months of 2024 and the comparable period in 2023, detailing changes in common stock, additional paid-in capital, treasury stock, retained earnings, and accumulated other comprehensive income. Specific dollar amounts for these accounts are presented as of June 30, 2024, and December 31, 2023.
Why It Matters
This filing provides investors with an update on Adagene's financial position as of the end of the second quarter, offering insights into the company's capital structure and retained earnings.
Risk Assessment
Risk Level: low — This is a routine financial filing (6-K) providing an update on the company's financial position, not announcing major strategic shifts or significant events.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial reporting period covered by the 6-K.)
- 2023-12-31 — Prior Year End Date (Provides a comparison point for financial data from the end of the previous fiscal year.)
Key Players & Entities
- Adagene Inc. (company) — Filer of the report
- 0001818838 (company) — Central Index Key for Adagene Inc.
- 20240630 (date) — Conformed period of report
- 20240725 (date) — Filing date
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to provide an update on Adagene Inc.'s financial position as of June 30, 2024, including details on its capital structure and equity accounts for the period ending June 30, 2024, and comparative periods.
What financial periods are covered in this filing?
This filing covers the period from January 1, 2024, to June 30, 2024, and includes comparative data for the period from January 1, 2023, to June 30, 2023, as well as year-end data for December 31, 2023.
What specific financial accounts are detailed in the filing?
The filing details accounts such as Common Stock, Additional Paid-In Capital, Treasury Stock (Common), Retained Earnings, and Accumulated Other Comprehensive Income.
What is Adagene Inc.'s SIC code?
Adagene Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When was this 6-K form filed with the SEC?
This 6-K form was filed with the SEC on July 25, 2024.
From the Filing
0001410578-24-001109.txt : 20240725 0001410578-24-001109.hdr.sgml : 20240725 20240725160554 ACCESSION NUMBER: 0001410578-24-001109 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 78 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240725 DATE AS OF CHANGE: 20240725 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adagene Inc. CENTRAL INDEX KEY: 0001818838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39997 FILM NUMBER: 241142065 BUSINESS ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-512-87773632 MAIL ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 6-K 1 adag-20240725x6k.htm 6-K 0001818838 2024-01-01 2024-06-30 0001818838 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001818838 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001818838 us-gaap:CommonStockMember 2024-06-30 0001818838 dei:AdrMember 2024-06-30 0001818838 us-gaap:CommonStockMember 2023-12-31 0001818838 dei:AdrMember 2023-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001818838 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001818838 us-gaap:TreasuryStockCommonMember 2024-06-30 0001818838 us-gaap:RetainedEarningsMember 2024-06-30 0001818838 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001818838 us-gaap:TreasuryStockCommonMember 2023-12-31 0001818838 us-gaap:RetainedEarningsMember 2023-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2023-06-30 0001818838 us-gaap:RetainedEarningsMember 2023-06-30 0001818838 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001818838 us-gaap:TreasuryStockCommonMember 2022-12-31 0001818838 us-gaap:RetainedEarningsMember 2022-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001818838 srt:MinimumMember adag:EmployeeAndExternalDirectorsMember adag:PerformanceIncentivePlan2021Member 2024-01-24 2024-06-30 0001818838 srt:MaximumMember adag:EmployeeAndExternalDirectorsMember adag:PerformanceIncentivePlan2021Member 2024-01-24 2024-06-30 0001818838 srt:MinimumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2023-04-12 2023-06-30 0001818838 srt:MaximumMember us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2023-04-12 2023-06-30 0001818838 2023-01-01 2023-12-31 0001818838 2022-01-01 2022-12-31 0001818838 adag:EmployeeAndExternalDirectorsMember adag:PerformanceIncentivePlan2021Member 2024-01-24 2024-06-30 0001818838 adag:ServiceConditionsAndPerformanceConditionsMember 2024-01-01 2024-06-30 0001818838 us-gaap:ShareBasedPaymentArrangementNonemployeeMember adag:PerformanceIncentivePlan2021Member 2023-04-12 2023-06-30 0001818838 us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2023-04-12 2023-06-30 0001818838 us-gaap:ShareBasedPaymentArrangementEmployeeMember adag:PerformanceIncentivePlan2021Member 2023-04-01 2023-04-30 0001818838 adag:ServiceConditionsAndPerformanceConditionsMember 2023-01-01 2023-06-30 0001818838 adag:ModificationOfVestingSchedulesAndConditionsOfShareOptionsMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-07 2022-01-07 0001818838 adag:SanofiAgreementMember 2024-01-01 2024-06-30 0001818838 adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember 2024-01-01 2024-06-30 0001818838 adag:ExelixisIncAgre